Grace Therapeutics (GRCE) Non Operating Interest Expenses (2019)
Grace Therapeutics' (GRCE) quarterly Non Operating Interest Expenses came in at $23000.0 in Q4 2019, down 23.33% quarter-over-quarter from $30000.0 in Q3 2019.
Powered by 
Analysis
Grace Therapeutics (GRCE) Non Operating Interest Expenses (2019) Analysis & Trends
Grace Therapeutics has disclosed Non Operating Interest Expenses across 1 years of filings, most recently posting $23000.0 for Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Grace Therapeutics | 34.18 Mn | 34.18 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 23,000.00 |
| Sep 30, 2019 | 30,000.00 |
| Jun 30, 2019 | 30,000.00 |